Skip to content

A Study to Compare the Effect of Lajjalu Arka with Sphatika Bhasma and Botroclot in Controlling Minor Bleeding

A Comparative Clinical Study To Evaluate The Hemostatic Effect Of Lajjalu Arka With Sphatika Bhasma And Botroclot In Capillary Bleeding. - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/102637
Enrollment
32
Registered
2026-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I789- Disease of capillaries, unspecified

Interventions

None listed

Sponsors

Dr. Lohith L Dev
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients undergoing minor surgical procedures, wound debridement, or para-surgical interventions (e.g., fissure bleeding, corn excision, ulcer cleaning). 2. Patients present with active capillary bleeding that does not require systemic intervention. 3. Bleeding that can be controlled by local hemostatic application. 4. Patients with normal platelet count and normal coagulation profile. 5. Patients who have signed informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with uncontrolled bleeding requiring surgical or systemic hemostatic measures. 2. Known cases of bleeding disorders (e.g., haemophilia, thrombocytopenia, von Willebrand disease). 3. Patients on anticoagulants or antiplatelet therapy (e.g., warfarin, aspirin, clopidogrel). 4. Known hypersensitivity any ingredients of Lajjalu Arka with Sphatika Bhasma or Botroclot. 5. Bleeding due to vascular malformations or deep-seated lesions.

Design outcomes

Primary

MeasureTime frame
1. Time taken for hemostasis. 2. Hemostasis status at intervals.Timepoint: 2.5 minutes

Secondary

MeasureTime frame
1. Reduced need for reapplication of the study medication to achieve effective control of minor bleeding. 2. Safety & tolerability of the treatment, assessed by the absence of local irritation, pain, or other adverse effects.Timepoint: 1. Reapplication if bleeding persists after 5 minutes. 2. Adverse effects assessed after 30 minutes of application.

Countries

India

Contacts

Public ContactDr Lohith L Dev

SDM Institute of Ayurveda and Hospital

drshankar@sdmayurbangalore.in9844669713

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026